These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
453 related items for PubMed ID: 10632283
1. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. JAMA; 2000 Jan 05; 283(1):74-80. PubMed ID: 10632283 [Abstract] [Full Text] [Related]
5. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. AIDS; 2004 Nov 19; 18(17):2277-84. PubMed ID: 15577540 [Abstract] [Full Text] [Related]
6. [Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection]. Rivero A, Camacho A, Pérez-Camacho I, Torre-Cisneros J. Enferm Infecc Microbiol Clin; 2008 Dec 19; 26 Suppl 17():45-8. PubMed ID: 20116617 [Abstract] [Full Text] [Related]
7. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan. Wu PY, Cheng CY, Liu CE, Lee YC, Yang CJ, Tsai MS, Cheng SH, Lin SP, Lin DY, Wang NC, Lee YC, Sun HY, Tang HJ, Hung CC. PLoS One; 2017 Dec 19; 12(2):e0171596. PubMed ID: 28222098 [Abstract] [Full Text] [Related]
12. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. J Infect Dis; 2002 Jul 01; 186(1):23-31. PubMed ID: 12089658 [Abstract] [Full Text] [Related]
13. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA. AIDS; 2003 Oct 17; 17(15):2191-9. PubMed ID: 14523276 [Abstract] [Full Text] [Related]
17. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Aranzabal L, Casado JL, Moya J, Quereda C, Diz S, Moreno A, Moreno L, Antela A, Perez-Elias MJ, Dronda F, Marín A, Hernandez-Ranz F, Moreno A, Moreno S. Clin Infect Dis; 2005 Feb 15; 40(4):588-93. PubMed ID: 15712082 [Abstract] [Full Text] [Related]
18. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients. Ena J, Amador C, Benito C, Fenoll V, Pasquau F. Int J STD AIDS; 2003 Nov 15; 14(11):776-81. PubMed ID: 14624743 [Abstract] [Full Text] [Related]